Newbridge Financial Services Group, Inc. Aridis Pharmaceuticals, Inc. Transaction History

Newbridge Financial Services Group, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Oct 27, 2021	SELL	$3.55 - $7.49 $1,420 - $2,996	-400 Closed	0 $0
Q2 2021 Sep 07, 2021	BUY	$5.3 - $7.4 $2,120 - $2,960	400 New	400 $3,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.